Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

7.605 +0.285 (+3.89%)

Streaming Delayed Price Updated: 12:45 PM EDT, Apr 17, 2026 Add to My Watchlist

Price and Volume

Volume	2,463,634
Open	7.450
Bid (Size)	7.600 (600)
Ask (Size)	7.610 (500)
Prev. Close	7.320
Today's Range	7.253 - 7.645
52wk Range	5.020 - 21.73
Shares Outstanding	98,983,261
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wave Life Sciences Announces Proposed Redomiciliation to the United States

April 15, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Is This Weight Loss Drug Stock a Buy on the Dip? ↗

April 01, 2026

This company's anti-obesity candidate might succeed where others are failing.

Via The Motley Fool

Performance

YTD	-52.3%	-52.3%
1 Month	-39.0%	-39.0%
3 Month	-45.9%	-45.9%
6 Month	-3.4%	-3.4%
1 Year	+30.2%	+30.2%

More News

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints ↗

March 26, 2026

Via The Motley Fool

Wave Life Sciences Ltd (NASDAQ:WVE) Reports Mixed Q4 2025 Results, Highlights Extended Cash Runway to 2028 ↗

February 26, 2026

Via Chartmill

Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗

March 26, 2026

Via Chartmill

Here are the top movers in Thursday's session. ↗

March 26, 2026

Via Chartmill

Thursday's session: gap up and gap down stocks ↗

March 26, 2026

Via Chartmill

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

These stocks that are showing activity before the opening bell on Thursday. ↗

March 26, 2026

Via Chartmill

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

March 26, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

March 05, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences (WVE) Earnings Call Transcript ↗

February 27, 2026

Via The Motley Fool

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

February 19, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

February 02, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

From BioMedWire

Via GlobeNewswire

This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company. ↗

January 14, 2026

Via The Motley Fool

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

January 12, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 06, 2026

Via Chartmill

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

December 11, 2025

Via Chartmill

Golden Cross Alert: 3 Stocks With Major Upside Potential ↗

December 10, 2025

Via MarketBeat

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 09, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Why Wave Life Sciences Stock Crushed it Again Today ↗

December 09, 2025

Via The Motley Fool

Frequently Asked Questions

Is Wave Life Sciences Ltd. - Ordinary Shares publicly traded?

Yes, Wave Life Sciences Ltd. - Ordinary Shares is publicly traded.

What exchange does Wave Life Sciences Ltd. - Ordinary Shares trade on?

Wave Life Sciences Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares?

The ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares is WVE on the Nasdaq Stock Market

What is the current price of Wave Life Sciences Ltd. - Ordinary Shares?

The current price of Wave Life Sciences Ltd. - Ordinary Shares is 7.605

When was Wave Life Sciences Ltd. - Ordinary Shares last traded?

The last trade of Wave Life Sciences Ltd. - Ordinary Shares was at 04/17/26 12:45 PM ET

What is the market capitalization of Wave Life Sciences Ltd. - Ordinary Shares?

The market capitalization of Wave Life Sciences Ltd. - Ordinary Shares is 752.77M

How many shares of Wave Life Sciences Ltd. - Ordinary Shares are outstanding?

Wave Life Sciences Ltd. - Ordinary Shares has 753M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.